within Pharmacolibrary.Drugs.N_NervousSystem.N06B_PsychostimulantsAgentsUsedForAdhdAndNootropics.N06BA15_DexmethylphenidateAndSerdexmethy;

model DexmethylphenidateAndSerdexmethy
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.22,
    Cl = 7.77777777777778e-06,
    adminDuration = 600,
    adminMass = 39.2 / 1000000,
    adminCount = 1,
    Vd = 0.00265,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.008333333333333333,
    Tlag = 600,
    Vdp = 0.0015,
    k12 = 9.722222222222221e-06,
    k21 = 9.722222222222221e-06);

  annotation (Documentation(
info       = "<html><body><table><tr><td>name:</td><td>DexmethylphenidateAndSerdexmethylphenidate</td></tr><tr><td>ATC code:</td><td>N06BA15</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dexmethylphenidate is the d-threo-enantiomer of methylphenidate, a central nervous system stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. Serdexmethylphenidate is a prodrug of dexmethylphenidate designed for extended-release formulations. The combination is approved and marketed for the treatment of ADHD.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for healthy adults based on known pharmacokinetics of dexmethylphenidate and serdexmethylphenidate (CNS stimulant, oral administration). No published non-compartmental or compartmental population PK modeling reports currently available; estimates extrapolated from clinical pharmacology data.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06BA15 folded in (Drugs.ATC removed)</li><li>06/2025 initial generated model</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end DexmethylphenidateAndSerdexmethy;
